Otsuka Pharmaceutical

History

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No. 2 drug maker by sales after industry leader Takeda Pharmaceutical Company.

Otsuka Pharmaceutical Co. Ltd Holdings

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.

In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.

In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.

In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.

In 2023, the company announced the acquisition of Mindset Pharma for $58.6 million.

Acquisition history

• Otsuka Pharmaceutical Co., Ltd
  • Ridge Vineyards (Acq 1986)
  • Crystal Geyser Water Company (Acq 1990)
  • Astex Pharmaceuticals (Merged 2011, Acq 2013)
    • Astex Therapeutics Limited
    • SuperGen, Inc
  • Avanir Pharmaceuticals (Acq 2014)
  • Daiya (Acq 2017)
  • ReCor Medical, Inc. (Acq 2019)
  • Otsuka America, Inc
    • Visterra (Acq 2019)
    • Neurovance, Inc (Acq 2017)
    • Mindset Pharma Inc (Acq 2023)
    • Jnana Therapeutics Inc. (Acq 2024)

Products

• CalorieMate
• Pocari Sweat
• Oronamin C
• Aripiprazole / Abilify
• Brexpiprazole / Rexulti
• Rejoyn
• SoyJoy

References

References

1. (December 16, 2010). "Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1".
2. (15 January 2020). "Tokushima Vortis".
3. (May 28, 2008). "Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A.".
4. (January 13, 2012). "Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead". BioSpace.
5. (January 13, 2012). "UCB and Otsuka to focus collaboration on CNS disorders". Zenopa.
6. (3 March 2017). "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN".
7. Howes, Laura. (September 9, 2023). "Otsuka to buy Mindset Pharma". [[Chemical & Engineering News]].
8. "Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 | Otsuka People Talk".
9. [https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library] {{Webarchive. link. (2019-06-16 , ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.)
10. Kelly, Tim. (September 5, 2013). "Japan's Otsuka to buy U.S. cancer firm Astex for $886 million". Reuters.
11. Soble, Jonathan. (2 December 2014). "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion".
12. "Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka".
13. "Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement".
14. (July 11, 2018). "Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms".
15. (3 March 2017). "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN".
16. (23 September 2024). "Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.".
17. "Aripiprazole". AdisInsight.
18. (2018). "Clinical Psychopharmacology: An Update". Springer.